$18.39
-10.14 (-35.54%)
Open$20.83
Previous Close$28.53
Day High$21.24
Day Low$17.77
52W High$27.93
52W Low$5.55
Volume—
Avg Volume355.3K
Market Cap721.23M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+49.0% upside
Current
$18.39
$18.39
Target
$27.40
$27.40
$23.46
$27.40 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 66.09M | 69.56M | 73.83M |
| Net Income | 7.65M | 9.76M | 11.38M |
| Profit Margin | 11.6% | 14.0% | 15.4% |
| EBITDA | 12.79M | 14.57M | 15.15M |
| Free Cash Flow | 6.98M | 8.54M | 10.02M |
| Rev Growth | +12.3% | +24.1% | -0.1% |
| Debt/Equity | 0.76 | 0.65 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |